Business Context and Reporting Period
This Form 6-K filing by Zai Lab Limited (Zai) covers the month of July 2020. The report details a strategic partnership entered into on July 7, 2020, between Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai, and Turning Point Therapeutics, Inc. (Turning Point).
Key Financial Metrics and Transaction Terms
The filing outlines a significant licensing agreement rather than standard periodic financial results. Key financial terms include:
- Upfront Payment: Zai will pay Turning Point an upfront cash payment of $25.0 million.
- Milestone Payments: Turning Point is eligible to receive up to $151.0 million in potential future payments, comprising up to $46.0 million in development milestones and up to $105.0 million in sales milestones.
- Royalties: Zai will pay tiered percentage royalties ranging from the mid-to-high teens on annual net sales of the products in the Territory.
- Financial Impact: The filing text does not provide specific values for Zai's current revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Strategic Developments
The primary material change is the acquisition of exclusive rights to develop and commercialize repotrectinib (the "Products") in Mainland China, Hong Kong, Macau, and Taiwan (the "Territory").
- Scope of Rights: Zai holds exclusive rights within the Territory, while Turning Point retains exclusive rights globally outside the Territory.
- Development Responsibilities: Zai is responsible for development and commercialization activities in the Territory at its own expense. Turning Point retains responsibility for global clinical studies, including portions conducted in the Territory, though Zai may participate in global studies at its own expense.
- Supply Arrangements: Turning Point will supply the Products to Zai for use in the Territory, though Zai retains the right to package and label the products.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the agreement. Key outlook factors and risks include:
- Future Opportunities: Zai has a first right to negotiate a license for up to two additional drug candidates from Turning Point's pipeline if Turning Point seeks to license them in the Territory.
- Change of Control: If Turning Point is acquired, the acquirer gains a first right to negotiate co-commercialization rights with Zai until Zai files its first regulatory approval application in the Territory.
- Termination Risks: Zai may terminate the agreement for convenience with notice. Turning Point may terminate if Zai challenges patent rights. Either party may terminate for material breach, insolvency, or if an acquirer engages in competing activities without divestiture.
- Post-Termination Rights: Upon termination (excluding natural expiration or certain terminations by Zai for cause), Turning Point retains a worldwide, perpetual license to exploit the Products.
Investor Verification Checklist
- Verify the exact timing and conditions for the $25.0 million upfront payment.
- Confirm the specific definitions of the development and sales milestones required to trigger the $151.0 million in potential payments.
- Review the detailed tiered royalty percentages and the specific adjustments applicable to net sales.
- Assess the impact of the non-compete clauses on Zai's existing or future pipeline within the Territory.
- Monitor the status of global clinical studies for repotrectinib to gauge the timeline for Zai's potential regulatory filings.